Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study
Internal and Emergency Medicine · 2026-08 · 21 (5) · 1733-1738
DOI: 10.1007/s11739-026-04360-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal and Emergency Medicine, online erschienen am 28.04.2026. Verfasst von Jessica Pepe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Cardiovascular Sciences, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. jessica.pepe@uniroma…. Hauptthemen laut MEDLINE: Denosumab, Celiac Disease, Osteoporosis, Bone Density Conservation Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Abstract (Originalsprache)
Patients with celiac disease have lower bone mineral density (BMD) and higher incidence of fractures compared to age- and sex-matched controls. There are no studies of denosumab, an antiresorptive drug, which is a fully human monoclonal antibody that binds the receptor activator of NFκB ligand (RANKL) in celiac patients with osteoporosis. The aim is to study the long-term effect of denosumab on BMD in celiac patients with osteoporosis on a gluten-free diet (GFD), compared to non-celiac osteoporotic patients. Fifteen celiac patients with osteoporosis and control subjects of the same age, sex, BMI, and fragility fractures were enrolled. At baseline, each patient underwent biochemical tests, spine X-ray, and DXA measurements, and the Charlson Comorbidity Index (CCI) was computed. At each visit (every 2 years ± 6 months), with a follow-up of 4 years, any adverse events or new clinical fractures, DXA measurements, and CCI were recorded. In celiac patients, a statistically significant median delta increase in total hip T -score of 0.11 compared to baseline was observed (ANOVA p < 0.05), while in the control group, it was 0.07 (ANOVA p < 0.05), with no difference between groups. New fractures occurred in the celiac group in five patients during the follow-up, and in two patients in the control group ( p = 0.38). No adverse events occurred during follow-up. In celiac patients with osteoporosis on GFD, denosumab, with up to 4 years of follow-up, increased hip BMD without adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Cardiovascular Sciences, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. jessica.pepe@uniroma1.it.
- Department of Medical and Cardiovascular Sciences, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
- Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Pepe, J., Colangelo, L., Santori, R., Occhiuto, M., Diacinti, D., Ettorre, E., Desideri, G., Minisola, S., & Cipriani, C. (2026). Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study. Internal and Emergency Medicine, 21(5), 1733-1738. https://doi.org/10.1007/s11739-026-04360-8
Vancouver
Pepe J, Colangelo L, Santori R, Occhiuto M, Diacinti D, Ettorre E, et al. Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study. Internal and Emergency Medicine. 2026;21(5):1733-1738. doi:10.1007/s11739-026-04360-8
BibTeX
@article{Pepe2026,
author = {Pepe, Jessica and Colangelo, Luciano and Santori, Rachele and Occhiuto, Marco and Diacinti, Daniele and Ettorre, Evaristo and Desideri, Giovambattista and Minisola, Salvatore and Cipriani, Cristiana},
title = {Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study},
journal = {Internal and Emergency Medicine},
year = {2026},
volume = {21},
number = {5},
pages = {1733--1738},
doi = {10.1007/s11739-026-04360-8}
}
EUVIMED